Concepedia

Naomi Molloy

NM

Statistics

Publications

3

Citations

108

H-Index

3

Active since

2021

Affiliations

Fulcrum Therapeutics (United States)(Current)

Oregon Health & Science University

City Of Hope National Medical Center

Colorado Blood Cancer Institute

Fred Hutch Cancer Center

Naomi Molloy is an author at Fulcrum Therapeutics (United States) specializing in immunotherapy, autoimmunity, and immunology.

Top concepts

Publications per year

2021–2021

3

Publications

3

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study

Christiane Querfeld, John A. Thompson, Matthew H. Taylor et al. · The Lancet Haematology · 2021 · 71 citations

, , +9

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Jeffrey A. Zonder, Dahlia Sano et al. · Blood · 2021 · 26 citations

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

James M. Foran, Michael Maris, Jennifer Kimberly Lue et al. · Blood · 2021 · 11 citations

1–3 of 3